Henlez mission is to transform the management of skin conditions by using enzymes.
Henlez’s pre-clinical lead development program, HEN-001, is an enzyme-based, topical application directed towards hidradenitis suppurativa (HS) – a highly stigmatizing and chronic inflammatory condition characterized by severe pain, malodorous drainage and permanent scarring of the armpits and groin. The company was founded 2019 by former Novozymes A/S scientist and current CEO Jeppe Mouritsen.
Develops restorative treatments for Pain, Hearing Loss, and Sensory Neuron Disorders.
Hoba Therapeutics is Danish biotech developing restorative treatments for pain, hearing loss, and sensory neuron disorders. HB-086 is under development for the treatment of pain in multiple chronic neuropathic pain indications. HB-086 is a non-opioid compound with a unique MoA targeting the peripheral nervous system to reverse neuropathic pain and thus targeting the underlying cause of the disease. HB-097 is a restorative treatment for sensorineural hearing loss. Preclinical data of HB-097 show both a preventive effect of hearing loss by protecting nerve cells and a regenerative effect by reversal of already induced damage.
Scenic Biotech is a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders
Scenic Biotech is leveraging its Cell-Seq discovery platform to identify genetic modifiers across multiple therapeutic areas. Its lead programs include an immuno-oncology program targeting QPCTL, and three rare diseases programs based on druggable genetic modifiers. The rare disease programs consist of; Niemann Pick disease, type C (NP-C1), a rare lipid storage disorder that affects lipid metabolism, and cholesterol are transported in human cells, Barth syndrome, an X-linked, lipid metabolism disorder that affects the heart, and a program to treat a severe heritable metabolic syndrome.
SACRA Therapeutics mission is to innovate therapeutic strategies based on RNA epigenetics to treat incurable solid and hematological cancers.
SACRA Therapeutics represents a strategic collaborative research enterprise between Cristian Bellodi ‘s team at Lund University and Red Glead Discovery, built upon the original findings by the Bellodi group unravelling key roles for RNA modifications and protein biosynthesis in stem and cancer cells. SACRA Therapeutics addresses unmet clinical needs by developing lead compounds to target RNA modifiers in common tumor types characterized by metabolic dysfunction of protein synthesis and dismal prognosis.
ArgusEye develops innovative sensor solutions for real-time monitoring of bioproduction systems and processes
ArgusEye is a spin-off company from Linköping University, Sweden. The company develops novel sensor systems based on nanoplasmonic sensing, which is an optical technique that enables a robust label-free detection of biomolecular interactions in real-time. By combining nanoplasmonic sensing with fiber optics, ArgusEye has developed a miniaturized sensing system with potential applications including monitoring of biopharmaceutical production processes, detection of pathogens and other contaminants in water systems, and miniaturized sensors for in situ and in vivo detection of biomarkers.
Pretzel is developing treatments to address the genetic roots of mitochondrial dysfunction.
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation.
Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.
IO Biotech is developing immune therapies i.e. checkpoint/cancer vaccines as new cancer therapies working synergistically with existing therapy.
The company is founded by leading clinical researches at Herlev Hospital in Denmark who showed in clinical trials in lung cancer patients that their proprietary checkpoint/cancer vaccines provided more than 3x increased survival. The company’s lead program is in phase II in melanoma, and additional programs targets head and neck cancers, lung cancer as well as other cancer indications.
Galecto Biotech develops new therapies for fibrotic diseases and inflammation based on inhibition of Galectins.
The Company is based on seminal research from Lund University, Sweden, exploring the role of a group of proteins called Galectins. The lead program is in late stage clinical development and addresses a novel therapeutic target for Ideopatic Pulmonary Fibrosis called Galectin-3. Additional programs targets other fibrotic diseases. Galecto listed on NASDAQ (US) in October 2020 and trades under the ticker symbol GLTO.
Develops novel nitric oxide donators which are selective for the pulmonary circulation, making them safe and without systemic side-effects.
Attgeno has developed Supernitro, a first in class therapy for the specific delivery of Nitric Oxide (NO) in the lung for prevention and treatment of pulmonary hypertension. By the donation of NO in the lungs, Supernitro replaces the decrease in NO production that is a well-known consequence of different diseases leading to increased risk for pulmonary hypertension, a condition associated with severe morbidity and mortality.
Developing small molecules for the treatment of gastric acid related diseases.
Cinclus Pharma is a Swedish biopharmaceutical company that is developing novel small molecules for the treatment of gastroesophageal reflux disease (GERD). The lead candidate, linaprazan glurate, belongs to a novel class of drugs, so called Potassium-Competitive Acid Blockers (P-CABs), that result in faster regulation of intragastric pH by a different mechanism of action compared to PPIs. The drug is in Phase 2 development in Europe and the US and has the potential to heal esophageal injuries and alleviate GERD symptoms more effectively than current pharmaceutical therapies including PPIs.
Strike Pharma’s development program is focused on selection of novel clinically-relevant candidates for use as immunotherapeutic vaccines in the treatment of solid tumors.
Headquartered in Uppsala, Sweden, Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology to take precision medicine to a new level, enabling development of truly individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor. Such highly targeted treatment offers the potential to not only increase therapeutic efficacy, but also to reduce dosage levels thereby minimizing the risk of side effects.
ISD-Immunotech is developing a first-in-class therapy to treat the most severe Systemic lupus erythematosus (SLE) patients.
ISD-Immunotech is developing a first-in-class therapy to treat the most severe Systemic lupus erythematosus (SLE) patients. The therapy works by dampening the action of an intracellular protein called STimulator of INterferon Genes (STING). STING is part of the innate immune system, the body’s first line of defense against pathogen invaders like bacteria and viruses.
one-carbon Tx is specialized in targeting proteins involved in one carbon metabolism and DNA damage and repair (DDR) as a way to induce cancer cell death.
Co-founded by the Helleday Laboratory at SciLifeLab and Karolinska Institutet in Sweden, the company’s scientific idea is based on seminal research in DDR synthetic lethal biology by one of the leading research groups in the area. one-carbon Tx is developing first-in-class inhibitors targeting MTHFD2, an oncofetal protein expressed during embryogenesis, silenced in adult cells and then re-expressed in cancer. The lead program targets a range of cancer indications including leukemias and solid tumors with significant unmet medical needs and market potential.
Synklino develops a new treatment that can eradicate CMV virus infection, a significant problem in transplant patients.
The company is based on research from Copenhagen University and the Technical University of Denmark. Synklino’s lead molecule, Syn002, targets a receptor called US28, which is expressed by cells infected with CMV virus. US28 is found in both latent and lytic infection, and thus Syn002 provide an effective treatment in all stages of the disease. The program is currently in pre-clinical development.
Sortina develops new first in class therapies for treatment of aggressive cancers such as triple negative breast cancer.
Sortina is a spin-out of Gotenborg University. The company develops new first in class therapies inhibiting sortilins, a group of molecules playing a key role in metastasis and growth of aggressive cancers. Sortina is currently in early development, optimizing its small molecule sortilin inhibitors before entering pre-clinical studies.